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Abstract
Due to high prevalence of hypertension (HT) in worldwide population, all aspects of this disease are studied in 
order to understand its pathogenesis and the influence on human body, as well as in order to find proper treatment. 
Impaired balance of autonomic nervous system (ANS) is taken into account as one of the main causes elevating 
blood pressure (BP). It seems that over-activation of sympathetic nervous system (SNS) is the most important factor 
in pathogenesis of HT. There are some methods which allow us to measure the sympathetic and parasympathetic 
nervous system activity. Some of them are described below and the influence of impaired ANS balance on HT de-
velopment is presented. Many different, natural and pathologic factors can cause SNS response, so the measurement 
of the sole ANS activity cannot fully answer the question about the pathomechanism underlying HT. In this paper, 
we present some hypotheses regarding possible mechanisms of the disease progression. In primary HT, impairment 
of baroreceptors response is considered one of such mechanisms. Another one is the influence of hyperinsulinemia 
on the activation of SNS in insulin resistant patients. A few other factors are considered, like obesity, salt intake, 
sodium retention and alcohol intake and they are described briefly in our paper. In secondary hypertension, SNS 
can be activated indirectly by comorbidities, and this pathomechanism is also discussed.
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Background
Taking into account very high occurrence of HT 
in the worldwide population, it is obvious that under-
standing the pathogenesis of this disease is especially 
important. Hypertension appears to affect 30–45% 
of the general European population and this number 
increases with age [1]. Uncontrolled HT increases the 
risk of fatal cardiac, cerebral and renal events and leads 
to target organ damage [2]. From the clinical point of 
view one can differentiate primary and secondary HT. 
Essential HT (EHT) is the most common in popu-
lation and accounts for over 90% of all HT cases [3]. 
It is described as HT, in which there are no secondary 
causes of increased BP [4]. The essential hyperten-
sion is a highly heterogeneous disease and does not 
have one assigned pathomechanism, however it is 
considered a result of coexistence of many patholo-
gic factors [5, 6]. The autonomic nervous system is 
considered the main factor taking part in the origin of 
EHT with the specified predominant role of SNS [7]. 
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Activation may be spontaneous, stemming from di-
rect ANS pathology or caused by so called hyperten-
sinogenic factors such as obesity, insulin resistance, 
high alcohol intake, high salt intake, stress and dys-
lipidemia [3]. The possible mechanisms of mentioned 
SNS activation are described below. Secondary HT 
occurs as a result of other diseases. The most common 
are: renovascular disease, renal failure, aldosteronism, 
pheochromocytoma, mendelian forms, obstructive 
sleep apnea, and drug administration [8].
Measurement methods
There are papers showing the primary role of the 
ANS in EHT [9–12]. In early stages of HT, which 
are characterized by hyperkinetic circulation, re-
duced activity of parasympathetic nervous system 
was observed. To investigate this phenomena Julius 
et al. performed a study using the method which is 
based on intravenous injection of atropine preceded 
by intravenous injection of propranolol [9]. Atropine 
is an antagonist of acetylcholine — the vagal nerve 
neurotransmitter. Atropine combines with muscari-
nic receptors in the heart and prevents normal im-
pact of acetylcholine on heart function modulation. 
As a result of intravenous injection of atropine, heart 
rate and cardiac output increase [9, 13]. This change 
is smaller in EHT patients than in normotensive 
patients [9]. Exact data are shown in Table I.
Cardiac index after propranolol and atropine is an 
ave rage of two readings taken 5 and 7 min after the injec-
tion. Heart rate and cardiac index after propranolol and 
atropine represent readings after 7 min. Cardiac index = 
liters/min/m2; heart rate = beats/min. Based on [9]. 
Also administrating small doses of phenylephrine 
or nitroprusside to stimulate or deactivate barore-
ceptors might be used to test parasympathetic com-
ponent in baroreceptor reflex. Effect in essential hy-
pertensive patients was much less reflex bradycardia 
and tachycardia than in normotensive patients with 
superimposable results of muscle sympathetic nerve 
activity [10] (Table II).
Sympathetic nervous system activity can also be 
measured and it is proven that increased activation of 
SNS correlates with EHT occurrence [11, 14]. The 
first method to show this over-activation is measuring 
plasma catecholamine level. Catecholamines are con-
sidered an indirect index of SNS activation and were 
found to be increased in hypertensive patients [14] 
(Table III).
The second method is based on measurement of re-
gional norepinephrine overflow to plasma. Esler et al. 
proved that mean norepinephrine spillover is higher 
in primary hypertensive subjects than in normoten-
sive ones [11]. It also indicated on over-activation of 
SNS in the hypertensive subjects [11]. Level of SNS 
activation could also be assessed by microneurogra-
phy, which measures muscle sympathetic nerve activ-
ity. Grassi et al. conducted a study using this method. 
Table I. Mean and standard error of hemodynamic measurements after propranolol administration, and atropine administration in hyper-
tensive and normotensive patients
Patients (N = 11) Control subjects (N = 16) P value
On propranolol Cardiac index 3.23 ± 0.2 2.61 ± 0.1 < 0.01
Heart rate 65 ± 2.5 57.2 ± 2.3 < 0.05
On atropine after propranolol Cardiac index 3.63 ± 0.22 3.45 ± 0.14 Ns
Heart rate 98.4 ± 3.6 101 ± 3.6 Ns
Change: Propranolol to atropine Cardiac index +0.4 ± 0.17 +0.83 ± 0.2 < 0.05
Heart rate +33.4 ± 3.7 +43.9 ± 5 < 0.06
Table II. Heart rate and muscle sympathetic nerve activity (MSNA) sensitivity changes in 3 groups of patients after intravenous infusion of 
phenylephrine and nitroprusside
Normotensive Subjects (n = 15) Moderate EH (n = 14) Severe EH (n = 14)
Phenylephrine DHR/DMAP (b × min-1/mm Hg) –1.23 ± 0.2 –0.82 ± 0.1* –0.65 ± 0.1*
DMSNA/DMAP (%i.a./mm Hg) –6.72 ± 0.5 –6.48 ± 0.3 –7.21 ± 0.5
Nitroprusside DHR/ DMAP (b × min-1/mm Hg) –2.20 ± 0.1 –1.55 ± 0.2* –1.3 ± 0.1*
DMSNA/DMAP (%i.a./mm Hg) –13.0 ± 2.1 –12.5 ± 1.3 –13.7 ± 1.2
HR — heart rate; MAP — mean arterial pressure; MSNA — muscle sympathetic nerve activity; EH — essential hypertension; Mean arterial pressure gradient showed no significant differences between all groups of 
patients (based on [10]). *P < 0.01
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Table III. Reference values of plasma and urinary catecholamines levels
Adrenaline Supine (30 min) P < 273 pmol/L
Sitting P < 328 pmol/L
Standing (30 min) P < 4,914 pmol/L
U 0–109 nmol/24h
Noradrenaline Supine (30 min) P 650–2,423 pmol/L
Sitting P 709–4,019 pmol/L
Standing (30 min) P 739–4,137 pmol/L
U nmol/24h
*P — plasma, U — urine. Data taken from reference [15]
Table IV. Differences in microneurography results between hypertensive and normotensive patients
Normotensive Subjects (n = 15) Moderate EH (n = 14) Severe EH (n = 14)
MSNA, bursts per min 27.5 ± 2.5 39.2 ± 2.5 * 48.5 ± 2.4*,**
MSNA, bursts per 100 beats 40.3 ± 3.3 55.6 ± 4.12 * 68.2 ± 4.1*,**
MSNA — muscle sympathetic nerve activity; EH — essential hypertension (based on [10]). *P < 0.01 vs controls; **P < 0.01 vs moderate EH
They placed a microelectrode in the peroneal nerve. 
Compared results of hypertensive and normotensive 
subjects confirmed that increased activation of SNS 
occurred in EHT. The same study revealed that mus-
cle sympathetic nerve activity was not increased in 
subjects with secondary HT [10] (Table IV).
Proposed mechanisms in essential 
hypertension
All tests described above show that the ANS func-
tion is changed in patients with EHT in compar-
ison to normotensive ones [9, 10, 12, 16]. There 
are a couple of possible mechanisms thought to be 
responsible for EHT [6, 17–25]. The first possible 
explanation is the impairment of baroreceptors res-
ponse. The parasympathetic nervous system is not 
able to inhibit the increase of BP as it happens in 
normally functioning baroreflex [17]. As a result, 
sympathetic tone prevails in modulation. Despite 
impairment of parasympathetic component, sympa-
thetic tone is preserved. The baroreceptors sensitivity 
is reseting towards elevated BP and is considered an 
important component of high BP maintenance [26].
Other proposed mechanism is influence of hyper-
insulinemia in insulin resistant patients on activation 
of SNS [18]. The theory was created after study on 
animals and humans in which a high dose of insulin 
was given to subjects and the SNS activation was 
noticed [27, 28].
Obesity is the next important and common hyper-
tensinogenic factor [29]. Few mechanisms of obese 
increased sympathetic activity have been suggested, 
including the role of rennin-angiotensin-aldosterone 
system from which angiotensin II is considered an 
active agent causing sympathetic activation and pres-
sor responses, role of impaired baroreceptor sensivity, 
hyperinsulinemia, increased free faty acids crircula-
tion and adipokines level [19]. Animal models with 
high fat and carbohydrate intake developed a signif-
icant rise in BP due to enhanced peripheral alpha-1- 
and beta-adrenergic receptor sensitivity [30]. Cor-
responding results were reported in human studies. 
Blood pressure of the obese patients after one month 
of alpha- and beta-adrenergic receptor pharmacolog-
ical blockade was reduced noticeably more than BP 
of the lean ones [31].
Series of studies proved the role of salt intake and so-
dium retention as HT impact factors, and now it is ac-
cepted as common knowledge [20–23]. Over the years, 
the concept of salt sensitivity has been established as 
a result of observation of heterogeneous responses to 
salt intake and divided patients into salt sensitive and 
salt resistant in both, normal and HT groups [32, 33]. 
Results from the study showing high salt intake asso-
ciated with SNS activation are shown in Table V [34].
HouRong et al. revealed that plasma norepinephrine 
concentration, indirect index of SNS activity le vel, 
was elevated and significantly higher in salt sensitive 
patients compared to salt resistant individuals [32].
The high intake of alcohol can also influence ANS 
activity and there are several possible explanations to 
this phenomenon. These are: the induction of central 
nervous system, the reduction of baroreceptor reflex-
es, SNS activation or discharge of catecholamine or 
activation of renine-angiotensin-aldosterone system 
[6, 24, 25].
arterial hypertension 2016, vol. 20, no. 1
24 www.ah.viamedica.pl
Secondary hypertension and autonomic 
nervous system
Autonomic nervous system can also be involved 
in secondary hypertension. As a result of primary 
disease, ANS is secondarily activated and leads to 
HT [35–39]. Hypothyroidism is one of such diseases 
[36–38]. The possible explanation of the association 
between hypothyroidism and HT might be the influ-
ence of thyroid hormones on SNS probably by regu-
lating adrenergic receptor function and density [36, 
37, 40]. The number of beta-adrenergic receptors is 
decreased, therefore, a-adrenergic responses increase 
what possibly leads to the increase in systemic vascu-
lar resistance [37].
The next disease worth mentioning is hyperpara-
thyroidism. Parathormone has a direct effect on re-
nin secretion. Activation of the renin-angiotensin-al-
dosterone axis and enhanced sensitivity to the nor-
epinephrine may contribute to the prevalence of HT 
and to the vessel sensitization to pressor agents [41]. 
Also, renin-angiotensin-aldosterone axis is activated 
in renovascular diseases. Due to chronic ischemia 
of kidney caused by renal artery stenosis, the secre-
tion of renin is significantly increased which leads 
to high level of angiotensin in plasma [42, 43]. It is 
necessary to mention obstructive sleep apnea as an 
important SNS activating disorder [44]. Although 
obstructive sleep apnea elevates SNS output due to 
multiple pathways, hypoxemia is suggested to be the 
main factor [45–47]. Intermittent hypoxia results 
in BP elevation that persist even after removal of 
hypoxemic factor [48]. Possible mechanisms include 
abnormal baroreceptor reflex function and impaired 
chemoreflex sensitivity [49–51]. Chen et al. suggest-
ed the role of endothelin in hypoxemia-induced in-
crease of chemoreceptor activity. Functional studies 
revealed that endothelin increases stimulus-evoked 
intracellular Ca2+ levels, thereby potentiates che-
moreceptor responses [52]. Continuous hypoxemia 
increase expression of endothelin A receptor and 
of preproendothelin in the carotid body, therefore 
enhance chemoreceptor activity [53]. Another mech-
anism causing HT could be gene mutations. There 
are a few described mutations, which induce HT by 
different pathways. These mutations may influence 
hormone metabolism and lead to disturbances in 
renin-angiotensin-aldosterone system. Mutations can 
affect many other genes important in appropriate 
modulation of BP but this topic goes beyond this 
article and mechanism and more examples will not 
be discussed more accurately [54].
Conclusions
Understanding the mechanisms of HT, in this 
case these correlated to ANS, may provide impor-
tant information about the appropriate prevention, 
treatment or even the prediction of HT progression 
itself or other concomitant diseases. Induced SNS 
activity in HT may lead to left ventricle hypertrophy 
and hypertrophy and remodeling of arterial walls so 
the effective treatment is crucial. Discussed papers 
provide strong evidence for the role of ANS in the 
pathomechanism of HT. Antihypertensive therapy 
should concentrate more on having an influence on 
ANS. Such effect can be obtained by non-pharmaco-
logical therapy, antihypertensive drugs or as a result 
of both. Despite many studies conducted in this area, 
there are still many mechanisms that need to be re-
vealed to improve our knowledge and to fully explain 
the pathomechanism of HT.
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